People · Operator

Douglas Grant McFadden, Ph.D.

Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology

Companies

Filings

$58.0M

Combined raised · real

Single

Operator type

Companies

Company	Role	Sector	Stage	Raised · real	Value · est	Tied
OncoMyx Therapeutics, Inc.	—	Biotechnology	Series C	$58.0M	$1.2B	2019

Operator network

Douglas Grant McFadden, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Douglas Grant McFadden, Ph.… Company Co-operator (ring = serial)Hover to isolate ties · click to open

Co-operators (shared boards)

People named alongside Douglas Grant McFadden, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

Operator	Shared	Their companies
Steven J. Potts, Ph.D.	1	1
Kanad J. Das, Ph.D.	1	1
Ting J. Xiao, C.F.A., F.R.M.	1	1
Benjamin J. Rovinski, Ph.D.	1	1
Widya J. Mulyasasmita, Ph.D.	1	1
Charles M. Baum, M.D., Ph.D.	1	1
Leslie M. Sharp, Ph.D.	1	1
Ting G. Xiao	1	1
Jason G. Rushton	1	1
Kanad G. Das, Ph.D.	1	1
Michael G. Wood	1	1

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.